B&K Corporation Limited

B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities in China. The company primarily focuses on the discovery, development, and commercialization of therapies for wound healing, currently platelet-derived growth factor (“PDGF”) drugs. The company's pipeline comprised two Core Products including Pro-101-1 for the treatment of deep second-degree thermal burns, which has completed the statistical data analysis for Phase IIb clinical trial, and for the treatment of superficial second-degree thermal burns, which has reached last-patient-out but no statistical data was yet available; and Pro-101-2 for the treatment of diabetic foot ulcers. The company's products are to address both acute and chronic wounds as well as minor and hard-to-heal wounds including thermal burns, DFUs, fresh wounds, pressure ulcers, radiation ulcers, dry eye syndrome, corneal injury, photodermatitis, alopecia, hemorrhoids, and gastric ulcers. Additionally, its products include Pro-101-3, a topical gel for wounds, ulcers, alopecia, photodermatitis, and hemorrhoids; Pro-102, a spray for fresh wounds and photodermatitis; Pro-103, eye drops for dry eye syndrome and corneal injury; Pro-104, a drug device combination product for alopecia; Pro-105 for gastric ulcers; and injections. The company was formerly known as Beijing Zhonghong Saisi Biotechnology Limited and changed its name to B&K Corporation Limited in April 2024. The company was incorporated in 2012 and is based in Qingdao, China.